依达拉奉对急性脑梗塞并胰岛素抵抗病人空腹胰岛素及胰岛素抵抗指数水平的影响

Effect of Edaravone on FINS and HOMA-IR Levels in Patients with Acute Cerebral Infarction and Insulin Resistance

目的:研究依达拉奉(EDA)对急性脑梗塞(ACI)并胰岛素抵抗(IR)病人空腹胰岛素(FINS)及胰岛素抵抗指数(HOMA-IR)的影响。方法:选取我院2011年7月-2013年7月收治的152例ACI合并IR病患,随机分成2组。观察组给予EDA治疗,对照组仅实施常规治疗。比较两组空腹血糖,FINS以及HOMA-IR变化情况,并对比两组疗效。结果:观察组在治疗后的FINS为(17.39±3.56)mU/L,HOMA-IR为4.55±0.65,较同组治疗前的(30.44±4.28)mU/L,8.16±1.45;以及对照组在治疗后的(27.79±4.33)mU/L,7.83±0.88明显更低。观察组基本痊愈率为68.42%(52/76)、总有效率为97.37%(74/76),均显著高于对照组的47.37%(36/76)、82.89%(63/76)。差异均具有统计学意义(均P<0.05)。结论:EDA治疗ACI合并IR病患,能有效降低病患FINS以及HOMA-IR水平,且疗效显著,值得推荐。

Objective： To study the effect of edaravone （EDA） on fasting insulin（FINS） and homeostasis model assessment insulin resistance（HOMA-IR） levels in patients with acute cerebral infarction （ACI） and insulin resistance （IR）. Methods： The total of 152 cases ACI with IR patients in our hospital from July 2011 to July 2013 was randomly divided into two groups. The patients in EDA group were treated with EDA, while control group only received routine treatment. Fasting blood glucose, FINS, HOMA-IR changes, and curative effect were compared between the two groups. Results： After treatment, FINS and HOMA-IR levels in EDA group decreased significantly from （17.39±3.56） mU/L to （30.44±4.28） mU/L, and from 4.55±0.65 to 8.16±1.45, respecively; and decreased more significantly than in control group （versus [27.79±4.33] and [7.83±0.88] mU/L, respectively, P〈0.05）. The basic recovery rate （68.42%, 52/76） and total effective rate （97.37%, 74/76） in EDA group were higher than in control group （versus 47.37% and 82.89%, respectively, P〈0. 05）. Conclusion： HOMA-IR levels in patients with ACI and IR.